Article Text

Download PDFPDF

Comorbidity and age in the modelling of stroke: are we still failing to consider the characteristics of stroke patients?
  1. Sarah K McCann1,
  2. Catherine B Lawrence2
  1. 1 QUEST - Center for Transforming Biomedical Research, Berlin Institute of Health (BIH), Charité - Universitätsmedizin Berlin, Berlin, Germany
  2. 2 Division of Neuroscience and Experimental Psychology and Lydia Becker Institute of Immunology and Inflammation, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK
  1. Correspondence to Dr Catherine B Lawrence, Manchester Academic Health Science Centre, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom; catherine.lawrence{at}manchester.ac.uk; Dr Sarah K McCann, Charité - Universitätsmedizin Berlin, Berlin, Germany; sarah.mccann{at}charite.de

Abstract

Embedded Image

Stroke is a significant cause of mortality and morbidity for which there are limited treatment options. Virtually all drug interventions that have been successful preclinically in experimental stroke have failed to translate to an effective treatment in the clinical setting. In this review, we examine one of the factors likely contributing to this lack of translation, the failure of preclinical studies to consider fully the advanced age and comorbidities (eg, hypertension or diabetes) present in most patients with stroke. Age and comorbidities affect the likelihood of suffering a stroke, disease progression and the response to treatment. Analysing data from preclinical systematic reviews of interventions for ischaemic stroke we show that only 11.4% of studies included an aged or comorbid model, with hypertension being the most frequent. The degree of protection (% reduction in infarct volume) varied depending on the comorbidity and the type of intervention. We consider reasons for the lack of attention to comorbid and aged animals in stroke research and discuss the value of testing a potential therapy in models representing a range of comorbidities that affect patients with stroke. These models can help establish any limits to a treatment’s efficacy and inform the design of clinical trials in appropriate patient populations.

  • stroke
  • comorbidity
  • ischaemia
  • aged
  • preclinical
https://creativecommons.org/licenses/by/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors Conceptualisation: CBL. Methodology: SKM. Formal analysis: SKM. Data curation: CBL, SKM. Writing—original draft: CBL, SKM. Writing—review and editing: CBL, SKM.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; externally peer reviewed.

  • Data availability statement Data are available in a public, open access repository https://camarades.shinyapps.io/SRMed/

  • Open data This article was not formally reregistered. The data are available at https://camarades.shinyapps.io/SRMed/. The materials used are widely available.

  • Open peer review Prepublication and Review History is available online at http://dx.doi.org/10.1136/bmjos-2019-100013.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.